Table 1. Comparison of Patient, Tumor and Treatment Characteristics in Both Departments.
| Initial Management |
Univariate Statistics | ||
|---|---|---|---|
| Biopsy | Resection | ||
| Patient characteristics | |||
| Number of patients | 77 | 49 | |
| Year of first diagnosis, (IQR), y | 2006 (2005–2008) | 2008 (2006–2011) | p = 0.0025 |
| Sex | p = 0.24 | ||
| Male | 50 (65%) | 37 (76%) | |
| Female | 27 (35% | 12 (25%) | |
| Age at diagnosis, median (IQR), y | 44 (35–60) | 39 (33–46) | p = 0.096 |
| Follow-up, median, (IQR), y | 4.3 (2.1–8.2) | 5.6 (4.0–8.9) | P = 0.066 |
| Status | χ2 (2, N = 126) = 10.4 p = 0.005 | ||
| Dead | 43 (56%) | 13 (27%) | |
| Alive | 31 (40%) | 33 (67%) | |
| Unknown | 3 (4%) | 3 (6%) | |
| Overall Survival, median, y | 6.7 | Not reached | p = 0.003 |
| 5-year survival rate (%) | 54% | 82% | |
| 10-year survival rate (%) | 38% | 69% | |
| Preoperative KPS, mean (SD), % | 90 (8.1) | 92 (8.6) | p = 0.08 |
| Charlson comorbidity index, mean (SD) | 0.32 (1.1) | 0.37 (0.8) | p = 0.19 |
| Initial symptoms | χ2 (3, N = 126) = 0.45 p = 0.93 | ||
| None (incidental) | 5 (6%) | 2 (4%) | |
| Seizure | 49 (64%) | 34 (69%) | |
| Headache | 10 (13%) | 6 (12%) | |
| Neurological deficit | 23 (30%) | 15 (31%) | |
| Pignatti score, mean (SD) | 1.8 (1.0) | 1.7 (1.3) | p = 0.39 |
| Tumor Characteristics | |||
| Histopathology | χ2 (2, N = 126) = 8.5 p = 0.014 | ||
| Astrocytoma WHO°II | 44 (57%) | 18 (37%) | |
| Oligoastrocytoma WHO°II | 27 (35%) | 19 (39%) | |
| Oligodendroglioma WHO°II | 6 (8%) | 12 (24%) | |
| Tumor size | |||
| Maximum diameter, mean, (SD), mm | 50 (19) | 58 (23) | p = 0.051 |
| Tumor volume, mean, (SD), mm3 | 54 (53) | 75 (61) | p = 0.045 |
| Eloquent location (Sawaya-Score) | χ2 (2, N = 126) = 3.2 p = 0.20 | ||
| 1 | 5 (6%) | 8 (16%) | |
| 2 | 46 (60%) | 25 (51%) | |
| 3 | 26 (34%) | 16 (33%) | |
| Bilateral tumor extension | 4 (5%) | 3 (6%) | p = 1.00 |
| Left Hemisphere | 45 (58%) | 25 (51%) | p = 0.45 |
| Preoperative contrast enhancement | 14/73§ (19%) | 13/41§ (32%) | p = 0.17 |
| Location of tumor | χ2 (4, N = 126) = 5.0 p = 0.29 | ||
| Frontal | 29 (38%) | 22 (45%) | |
| Temporal | 10 (13%) | 11 (22%) | |
| Parietal | 7 (9%) | 2 (4%) | |
| Insula | 20 (26%) | 11 (22%) | |
| Other | 11 (14%) | 3 (6%) | |
| Surgical Characteristics | |||
| Number of tumor resections | |||
| 0 (Biopsy only) | 55 (71%) | — | |
| 1 | 13 (17%) | 25 (51%) | χ2 (2, N = ) = 2.2 p = 0.34 |
| 2 | 6 (8%) | 21 (43%) | χ2 (2, N = ) = 2.2 p = 0.34 |
| >2 | 3 (4%) | 3 (6%) | |
| Post operative deficits† | 0 (0%) | 7 (14%) | p = 0.001 |
| Post-operative deficits >6 months | 0 (0%) | 4 (8%) | p = 0.02 |
| χ2 (4, N = ) = 13.2 p = 0.011 | |||
| Adjuvant Therapy | Available: 66 (86%) | Available: 49 (100%) | χ2 (4, N = ) = 14.9 p = 0.005 |
| None | 22 (33%) | 23 (47%) | |
| Early radiotherapy | 22 (33%) | 2 (4%) | |
| Ever radiotherapy | 37 (56%) | 21 (43%) | |
| Early chemotherapy | 19 (29%) | 5 (10%) | |
| Ever chemotherapy | 41 (62%) | 23 (47%) | |
§Number of available pre-operative contrast-enhanced MRI.
†Deficits after first intervention (biopsy or 1st surgery), permanent deficit was defined as a new deficit persisting >6 months.